Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BAN2401: Phase II started

Eisai disclosed in its 1Q13 earnings for the period ending June 30 that it began a double-blind,

Read the full 171 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE